BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Atom Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Atom Therapeutics's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07323095-921@assetmemo.bio
DTSTAMP:20261121T005841Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Lingdolinurad: Phase 2 readout est. (NCT07323095)
DESCRIPTION:Lingdolinurad\, phase 2\, Chronic Kidney Disease.\nStudy: Evalu
 ate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Dis
 ease and Hyperuricaemia\nEstimated primary completion: 31 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lingdolinurad#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07323095
URL:https://assetmemo.bio/drug/lingdolinurad#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07303777-1128@assetmemo.bio
DTSTAMP:20261121T005841Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:ABP-745: Phase 2 readout est. (NCT07303777)
DESCRIPTION:ABP-745\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: Efficacy\, Safety\, and PopPK Profile of ABP-745 in Patients With Ath
 erosclerosis\nEstimated primary completion: January 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/abp-745#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07303777
URL:https://assetmemo.bio/drug/abp-745#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
